Walter R. Perkins
Chief Tech/Sci/R&D Officer presso INSMED INCORPORATED
Posizioni attive di Walter R. Perkins
Società | Posizione | Inizio | Fine |
---|---|---|---|
INSMED INCORPORATED | Chief Tech/Sci/R&D Officer | 01/12/2010 | - |
Storia della carriera di Walter R. Perkins
Precedenti posizioni note di Walter R. Perkins
Società | Posizione | Inizio | Fine |
---|---|---|---|
The Liposome Co., Inc.
The Liposome Co., Inc. Pharmaceuticals: MajorHealth Technology The Liposome Co., Inc. is a biopharmaceutical company engaged in the discovery, development, manufacturing and marketing of proprietary lipid- and liposome-based pharmaceuticals, primarily for the treatment of cancer and other related life-threatening illnesses. | Corporate Officer/Principal | - | - |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Chief Tech/Sci/R&D Officer | 01/01/2002 | - |
Formazione di Walter R. Perkins
University of Virginia | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
INSMED INCORPORATED | Health Technology |
Aziende private | 2 |
---|---|
The Liposome Co., Inc.
The Liposome Co., Inc. Pharmaceuticals: MajorHealth Technology The Liposome Co., Inc. is a biopharmaceutical company engaged in the discovery, development, manufacturing and marketing of proprietary lipid- and liposome-based pharmaceuticals, primarily for the treatment of cancer and other related life-threatening illnesses. | Health Technology |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
- Borsa valori
- Insiders
- Walter R. Perkins
- Esperienza